Top
Main

All outcomes

Feedback
Home
Top   Main   All Outcomes
Loading...
Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Vitamin C for COVID-19: real-time meta analysis of 30 studies
Covid Analysis, January 18, 2022, DRAFT
https://c19vitaminc.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Thomas (RCT) -204% 3.04 [0.13-72.9] death 1/48 0/50 Improvement, RR [CI] Treatment Control Thomas (RCT) 31% 0.69 [0.12-3.98] hosp. 2/48 3/50 Thomas (RCT) 18% 0.82 [0.63-1.07] recov. time 48 (n) 50 (n) Zhao (PSM) 72% 0.28 [0.08-0.93] progression 4/55 12/55 Zhao (PSM) -8% 1.08 [0.64-1.80] viral time 55 (n) 55 (n) Ried (RCT) 31% 0.69 [0.54-0.89] no recov. 69/162 46/75 Krishnan 31% 0.69 [0.47-0.92] death 40/79 52/73 Zhang (RCT) 50% 0.50 [0.20-1.50] death 6/27 11/29 Zhang (RCT) 80% 0.20 [0.10-0.90] death 5/27 11/29 Zhang (RCT) 50% 0.50 [0.20-1.80] death 6/27 10/29 Zhang (RCT) 70% 0.30 [0.21-1.10] death 5/27 10/29 Yüksel (PSM) 19% 0.81 [0.66-0.99] death 31/42 40/44 Patel 29% 0.71 [0.43-1.14] death 22/96 26/80 Patel 16% 0.84 [0.52-1.36] death 15/30 16/27 Kumari (RCT) 36% 0.64 [0.26-1.55] death 7/75 11/75 Kumari (RCT) 20% 0.80 [0.40-1.59] ventilation 12/75 15/75 Kumari (RCT) 26% 0.74 [0.64-0.86] recov. time 75 (n) 75 (n) Kumari (RCT) 24% 0.76 [0.66-0.87] hosp. time 75 (n) 75 (n) Darban (RCT) 33% 0.67 [0.14-3.17] progression 2/10 3/10 CT​1 Darban (RCT) 6% 0.94 [0.84-1.06] ICU 10 (n) 10 (n) CT​1 JamaliMog.. (RCT) 0% 1.00 [0.22-4.56] death 3/30 3/30 JamaliMog.. (RCT) -25% 1.25 [0.37-4.21] ventilation 5/30 4/30 JamaliMog.. (RCT) -31% 1.31 [1.03-1.66] hosp. time 30 (n) 30 (n) Gao 86% 0.14 [0.03-0.72] death 1/46 5/30 Hamidi-Ala.. (RCT) 44% 0.56 [0.20-1.51] death 5/40 9/40 CT​1 Hamidi-Ala.. (RCT) 38% 0.62 [0.45-0.86] hosp. time 40 (n) 40 (n) CT​1 Al Sulaiman (PSM) 15% 0.85 [0.61-1.12] death 46/142 59/142 Mulhem -32% 1.32 [1.07-1.62] death 157/794 359/2,425 Gadhiya -1% 1.01 [0.48-1.91] death 19/55 36/226 Hakamifard (RCT) 46% 0.54 [0.14-2.08] ICU 3/38 5/34 CT​1 Hakamifard (RCT) 1% 0.99 [0.91-1.07] hosp. time 38 (n) 34 (n) CT​1 Suna 21% 0.79 [0.44-1.41] death 17/153 24/170 Suna -2% 1.02 [0.46-2.24] ICU 11/153 12/170 Li (PSM) -11% 1.11 [0.79-1.54] death 7/8 19/24 Vishnuram 54% 0.46 [0.24-0.86] death 164/8,634 10/241 Özgünay 9% 0.91 [0.63-1.30] death 17/32 75/128 Özgünay -1% 1.01 [0.79-1.29] ventilation 23/32 91/128 Tan 25% 0.75 [0.10-2.98] int./death 1/46 14/115 CT​1 Tan 73% 0.27 [0.09-0.61] ARDS 7/46 41/115 CT​1 Zheng (PSM) -157% 2.57 [0.39-16.8] death 12/70 7/327 Zheng -169% 2.69 [0.91-7.89] death 12/70 7/327 Zheng (PSM) -35% 1.35 [0.88-2.08] no improv. 18/70 16/327 Zheng -32% 1.32 [0.93-1.82] no improv. 18/70 16/327 Simsek 44% 0.56 [0.23-1.35] death 6/58 15/81 Simsek 10% 0.90 [0.55-1.46] ICU 18/58 28/81 Tehrani (RCT) 87% 0.13 [0.01-2.25] death 0/18 4/26 Tehrani (RCT) 18% 0.82 [0.60-1.13] hosp. time 18 (n) 26 (n) Baguma -48% 1.48 [0.41-4.70] death 385 (n) 96 (n) Behera 18% 0.82 [0.45-1.57] cases case control Behera 29% 0.71 [0.40-1.26] cases case control Louca 0% 1.00 [0.97-1.04] cases Holt -3% 1.03 [0.77-1.39] cases 49/1,580 397/13,647 Abdulateef 19% 0.81 [0.37-1.78] hosp. 8/132 22/295 Mohseni -44% 1.44 [1.22-1.71] cases 34/43 307/560 vitamin C COVID-19 outcomes c19vitaminc.com Jan 18, 2022 1 CT: study uses combined treatment Favors vitamin C Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit